LGL Group, Inc. (The) (NYSEAMERICAN:LGL – Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totaling 23,373 shares, a growth of 103.9% from the April 30th total of 11,461 shares. Based on an average trading volume of 6,412 shares, the short-interest ratio is currently 3.6 days. Currently, 0.4% of the company’s stock are short sold.
Analysts Set New Price Targets
Separately, Zacks Research raised LGL Group to a “hold” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, LGL Group currently has a consensus rating of “Hold”.
View Our Latest Stock Report on LGL
Institutional Trading of LGL Group
LGL Group Stock Performance
Shares of LGL stock traded down $0.06 during trading on Monday, hitting $7.06. The company had a trading volume of 3,768 shares, compared to its average volume of 10,781. The firm has a market capitalization of $46.17 million, a P/E ratio of 706.71 and a beta of 0.31. LGL Group has a one year low of $5.45 and a one year high of $9.74. The stock’s 50-day moving average price is $7.07 and its 200 day moving average price is $6.68.
LGL Group (NYSEAMERICAN:LGL – Get Free Report) last released its quarterly earnings data on Monday, March 30th. The industrial products company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.09). The business had revenue of $0.80 million during the quarter, compared to analyst estimates of $9.10 million. LGL Group had a net margin of 1.66% and a return on equity of 0.16%. On average, research analysts anticipate that LGL Group will post -0.06 earnings per share for the current fiscal year.
About LGL Group
LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.
The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.
Recommended Stories
- Five stocks we like better than LGL Group
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
- Was Hormel’s Q2 Earnings Report the Turnaround Investors Needed?
Receive News & Ratings for LGL Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LGL Group and related companies with MarketBeat.com's FREE daily email newsletter.
